Clinical Trials Directory

Trials / Unknown

UnknownNCT06344936

Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects

Open-Label Assessment of the Effects of Itraconazole and Rifampicin on HRS-1780 Pharmacokinetics in Healthy Subjects

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
28 (estimated)
Sponsor
Shandong Suncadia Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects

Conditions

Interventions

TypeNameDescription
DRUGHRS-1780 tablets; Itraconazole capsules; Rifampicin capsulesTreatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice

Timeline

Start date
2024-04-01
Primary completion
2024-07-01
Completion
2024-07-01
First posted
2024-04-03
Last updated
2024-04-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06344936. Inclusion in this directory is not an endorsement.

Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects (NCT06344936) · Clinical Trials Directory